Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Tuberculosis

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tackling Health Inequity Through Focused Care in a 'Deep End' General Practice in England: A Case Study.

Journal of primary care & community health·2025

Same author

A nurse practitioner service in an adult tertiary intensive care unit: A prospective observational evaluation.

Australian critical care : official journal of the Confederation of Australian Critical Care Nurses·2025

Same author

A Missed Opportunity: Prioritizing the Development of a Healthy Market Ecosystem for Equitable Menstrual Health Within the International Conference on Population and Development Programme of Action.

Global health, science and practice·2025

Same author

Corrigendum to "Case management of a patient with botulism by an intensive care nurse practitioner team" [Aust Crit Care 38 (5) (2025) 101291].

Australian critical care : official journal of the Confederation of Australian Critical Care Nurses·2025

Same author

Case management of a patient with botulism by an intensive care nurse practitioner team.

Australian critical care : official journal of the Confederation of Australian Critical Care Nurses·2025

Same author

Severe nutritional anaemia in Yorkshire and the Humber following the COVID-19 pandemic: no room for complacency.

Archives of disease in childhood·2025

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)

A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)

Published on: April 30, 2020

Public-private partnership tackles TB challenges in parallel.

Nature Reviews. Drug Discovery

|August 1, 2009

Summary

The Global Alliance for TB Drug Development and Tibotec are collaborating on a novel drug to treat all forms of tuberculosis (TB). This potential first-in-class medication targets both drug-susceptible and drug-resistant TB infections.

Area of Science:

Pharmaceuticals and Medicinal Chemistry
Infectious Diseases
Microbiology

Background:

Tuberculosis (TB) remains a significant global health challenge, exacerbated by the rise of drug-resistant strains.
Existing treatment regimens for TB are lengthy and can be ineffective against resistant forms of the disease.

Discussion:

A collaborative effort between the Global Alliance for TB Drug Development and Tibotec aims to address unmet needs in TB treatment.
The focus is on developing a novel, first-in-class drug candidate with potential efficacy against both drug-susceptible and drug-resistant Mycobacterium tuberculosis.
This initiative represents a critical step towards combating multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).

Key Insights:

The partnership is pursuing a first-in-class therapeutic agent for tuberculosis.

Related Experiment Videos

Last Updated: Jun 21, 2026

A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)

A Tuberculosis Molecular Bacterial Load Assay (TB-MBLA)

Published on: April 30, 2020

The drug candidate is designed to be effective against a broad spectrum of TB, including resistant forms.

This development holds promise for improving treatment outcomes in patients with challenging TB infections.

Outlook:

Successful development could lead to a new cornerstone therapy for global TB control efforts.
Further clinical trials will be essential to establish the safety and efficacy of this novel drug.
This collaboration underscores the importance of public-private partnerships in tackling global health threats like tuberculosis.